Skip to main content
Top
Published in: Trials 1/2020

01-12-2020 | Central Nervous System Trauma | Research

Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results

Authors: Raoul Mansukhani, Lauren Frimley, Haleema Shakur-Still, Linda Sharples, Ian Roberts

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to treatment was recorded by clinicians and is subject to error. Using monitoring data from the CRASH-3 trial, we examine the impact of errors in time to treatment on estimated treatment effects.

Methods

The CRASH-3 trial was a randomised trial of the effect of tranexamic acid on death and vascular occlusive events in 12,737 TBI patients. This analysis includes the 8107 patients with a Glasgow coma scale score of 9 to 15 since previous analyses showed that these patients benefit most from early treatment. Clinician-recorded time to treatment was checked against ambulance and hospital records for 1368/12,737 (11%) patients. Patients who died were preferentially selected for monitoring and we monitored 36% of head injury deaths. We describe measurement errors using Bland-Altman graphs. We model the effect of tranexamic acid on head injury death using logistic regression with a time-treatment interaction term. We use regression calibration, multiple imputation and Bayesian analysis to estimate the impact of time to treatment errors.

Results

Clinicians rounded times to the nearest half or full hour in 66% of cases. Monitored times were also rounded and were identical to clinician times in 63% of patients. Times were underestimated by an average of 9 min (95% CI − 85, 66). There was more variability between clinician-recorded and monitored times in low- and middle-income countries than in high-income countries. The treatment effect estimate at 1 h was greater for monitored times OR = 0.61 (95% CI 0.47, 0.81) than for clinician-recorded times OR = 0.63 (95% CI 0.48, 0.83). All three adjustment methods gave similar time to treatment interactions. For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78). Using monitored times increased the time-treatment interaction term from 1.15 (95% CI 1.03, 1.27) to 1.16 (95% CI 1.05, 1.28).

Conclusions

Accurate estimation of time from injury to treatment is challenging, particularly in low resource settings. Adjustment for known errors in time to treatment had minimal impact on the trial results.

Trial registration

ClinicalTrials.gov NCT01402882. Registered on 25 July 2011
Appendix
Available only for authorised users
Literature
2.
go back to reference CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH- 2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.CrossRef CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH- 2): a randomised, placebo-controlled trial. Lancet. 2010;376:23–32.CrossRef
3.
go back to reference Adeyemi B, Dallaku K, Idris H, Wangui R, Gul J, Jabeen K, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16.CrossRef Adeyemi B, Dallaku K, Idris H, Wangui R, Gul J, Jabeen K, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16.CrossRef
4.
go back to reference Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet. 2018;391(10116):125–32.CrossRef Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40138 bleeding patients. Lancet. 2018;391(10116):125–32.CrossRef
6.
go back to reference Frost C, Thompson SG. Correcting for regression dilution bias: comparison of methods for a single predictor variable. J R Stat Soc Ser A Stat Soc. 2000;163(2):173–89.CrossRef Frost C, Thompson SG. Correcting for regression dilution bias: comparison of methods for a single predictor variable. J R Stat Soc Ser A Stat Soc. 2000;163(2):173–89.CrossRef
8.
go back to reference Bartlett JW, Seaman SR, White IR, et al. Multiple imputation of covariates by fully conditional specification: accommodating the substantive model. Stat Methods Med Res. 2015;24:462–87.CrossRef Bartlett JW, Seaman SR, White IR, et al. Multiple imputation of covariates by fully conditional specification: accommodating the substantive model. Stat Methods Med Res. 2015;24:462–87.CrossRef
11.
go back to reference Yarmey AD. Retrospective duration estimations for variant and invariant events in field situations. Appl Cogn Psychol. 2000;14(1):45–57.CrossRef Yarmey AD. Retrospective duration estimations for variant and invariant events in field situations. Appl Cogn Psychol. 2000;14(1):45–57.CrossRef
13.
go back to reference Parker BT, Marco C. Emergency department length of stay: accuracy of patient estimates. West J Emerg Med. 2014;15(2):170–5.CrossRef Parker BT, Marco C. Emergency department length of stay: accuracy of patient estimates. West J Emerg Med. 2014;15(2):170–5.CrossRef
15.
go back to reference Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35.CrossRef Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–35.CrossRef
16.
go back to reference Newby K. Clinical outcomes according to time to treatment. Clin Cardiol. 1997;20(S3):11–5.CrossRef Newby K. Clinical outcomes according to time to treatment. Clin Cardiol. 1997;20(S3):11–5.CrossRef
17.
go back to reference Wang D, Wang Y. Tissue window, not the time window, will guide acute stroke treatment. Stroke Vasc Neurol. 2019;4(1):1–2.CrossRef Wang D, Wang Y. Tissue window, not the time window, will guide acute stroke treatment. Stroke Vasc Neurol. 2019;4(1):1–2.CrossRef
18.
go back to reference Mahmoud KD, Hillege HL, Jaffe AS, Lennon RJ, Holmes DR. Biochemical validation of patient-reported symptom onset time in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8(6):778–87.CrossRef Mahmoud KD, Hillege HL, Jaffe AS, Lennon RJ, Holmes DR. Biochemical validation of patient-reported symptom onset time in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2015;8(6):778–87.CrossRef
21.
go back to reference Plummer M (2003). JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling, Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20–22, Vienna, Austria. ISSN 1609-395X. Plummer M (2003). JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling, Proceedings of the 3rd International Workshop on Distributed Statistical Computing (DSC 2003), March 20–22, Vienna, Austria. ISSN 1609-395X.
22.
go back to reference Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions (with discussion). Stat Med. 2009;28:3049–82.CrossRef Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions (with discussion). Stat Med. 2009;28:3049–82.CrossRef
23.
go back to reference Stan Development Team 2018. Stan modelling language users guide and reference manual, version 2.18.0 http://mc-stanorg Accessed 14 Feb 2020. Stan Development Team 2018. Stan modelling language users guide and reference manual, version 2.18.0 http://​mc-stanorg Accessed 14 Feb 2020.
24.
go back to reference Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012;13:87.CrossRef Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012;13:87.CrossRef
25.
go back to reference Roberts I, Belli A, Brenner A, Chaudhri R, Fawole B, Harris T, et al. Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Wellcome Open Res. 2018;3:86.CrossRef Roberts I, Belli A, Brenner A, Chaudhri R, Fawole B, Harris T, et al. Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial. Wellcome Open Res. 2018;3:86.CrossRef
Metadata
Title
Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results
Authors
Raoul Mansukhani
Lauren Frimley
Haleema Shakur-Still
Linda Sharples
Ian Roberts
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04623-5

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue